LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

Home・Akcijų sąrašas・Pulse Biosciences Inc

Pulse Biosciences Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

25.07 4.9

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.9

Max

25.62

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-217K -19M
Pardavimai	86K 86K
Pelnas, tenkantis vienai akcijai	-0.29
Pelno marža	-22,540.698
Darbuotojai	75
EBITDA	-228K -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+17.83% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-19

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-179M 958M
Ankstesnė atidarymo kaina	20.17
Ankstesnė uždarymo kaina	25.07

Naujienos nuotaikos

By Acuity

45%

55%

154 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

16.59 / 17.17 Palaikymas ir pasipriešinimas

Pulse Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-18 22:31; UTC

Uždarbis

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

2026-02-18 22:18; UTC

Uždarbis

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

2026-02-18 22:11; UTC

Uždarbis

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

2026-02-18 21:52; UTC

Uždarbis

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

2026-02-18 23:56; UTC

Rinkos pokalbiai

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

2026-02-18 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-18 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

2026-02-18 23:34; UTC

Rinkos pokalbiai

Uždarbis

Brambles' Cost Control Stands Out to Bull -- Market Talk

2026-02-18 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

2026-02-18 23:32; UTC

Rinkos pokalbiai

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

2026-02-18 22:45; UTC

Uždarbis

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

2026-02-18 22:44; UTC

Rinkos pokalbiai

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

2026-02-18 22:37; UTC

Uždarbis

Nutrien 4Q EPS $1.18 >NTR.T

2026-02-18 22:37; UTC

Uždarbis

Nutrien 4Q Sales $5.34B >NTR.T

2026-02-18 22:35; UTC

Uždarbis

Pan American Silver 4Q EPS $1.07 >PAAS

2026-02-18 22:35; UTC

Uždarbis

Pan American Silver 4Q Rev $1.18B >PAAS

2026-02-18 22:30; UTC

Uždarbis

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

2026-02-18 22:29; UTC

Uždarbis

Kinross Gold 4Q EPS 75c >K.T

2026-02-18 22:22; UTC

Uždarbis

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

2026-02-18 22:22; UTC

Rinkos pokalbiai

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

2026-02-18 22:16; UTC

Uždarbis

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

2026-02-18 22:05; UTC

Uždarbis

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

2026-02-18 22:03; UTC

Uždarbis

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q Sales $929M >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q EPS $1.68 >KALU

2026-02-18 22:00; UTC

Uždarbis

Kinross Gold 4Q Adj EPS 67c >KGC

2026-02-18 22:00; UTC

Uždarbis

Kinross Gold 4Q Sales $2.02B >KGC

2026-02-18 21:56; UTC

Uždarbis

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

2026-02-18 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Pulse Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

17.83% į viršų

12 mėnesių prognozė

Vidutinis 30 USD 17.83%

Aukščiausias 30 USD

Žemiausias 30 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pulse Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Pulse Biosciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

16.59 / 17.17Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

154 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.